Contract research organizations (CROs) provide substantial global capacity to drug developers and have become a critical contributor to clinical trial activity, according to the results of a study released by the Tufts Center for the Study of Drug Development. The study was based on an analysis of 83 NDAs and BLAs submitted to the FDA between 2000 and 2005. The study found that drug sponsors who use CROs more extensively complete projects faster, particularly during the study close-out peri...